Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
51
LIVN Quote, Financials, Valuation and Earnings
Last price:
$63.09
Seasonality move
:
0.55%
Day range:
$63.00 - $63.69
52-week range:
$32.48 - $65.57
Dividend yield:
0%
P/E ratio:
38.16x
P/S ratio:
2.56x
P/B ratio:
2.98x
Volume:
188.5K
Avg. volume:
633.9K
1-year change:
34.93%
Market cap:
$3.4B
Revenue:
$1.3B
EPS (TTM):
-$4.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LIVN
LivaNova Plc
|
$342.3M | $0.92 | 9.77% | -20.8% | $70.64 |
|
ABT
Abbott Laboratories
|
$11.4B | $1.30 | 7.51% | -71.7% | $144.43 |
|
CATX
Perspective Therapeutics, Inc.
|
$206.8K | -$0.32 | -9.65% | -37.91% | $12.3077 |
|
NVCR
NovoCure Ltd.
|
$158.9M | -$0.42 | 4.75% | -35.35% | $24.79 |
|
RMD
ResMed, Inc.
|
$1.3B | $2.50 | 8.96% | 16.17% | $291.80 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$32.7M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LIVN
LivaNova Plc
|
$63.08 | $70.64 | $3.4B | 38.16x | $0.00 | 0% | 2.56x |
|
ABT
Abbott Laboratories
|
$124.87 | $144.43 | $217.1B | 15.66x | $0.59 | 1.89% | 4.98x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8150 | $12.3077 | $209.3M | -- | $0.00 | 0% | 190.87x |
|
NVCR
NovoCure Ltd.
|
$13.44 | $24.79 | $1.5B | -- | $0.00 | 0% | 2.31x |
|
RMD
ResMed, Inc.
|
$244.44 | $291.80 | $35.7B | 25.02x | $0.60 | 0.93% | 6.84x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.78 | $1.50 | $108.9M | 76.27x | $0.00 | 0% | 0.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LIVN
LivaNova Plc
|
29.6% | 1.882 | 17.01% | 1.05x |
|
ABT
Abbott Laboratories
|
20.25% | 0.426 | 5.99% | 1.12x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
NVCR
NovoCure Ltd.
|
70.04% | -1.015 | 55.15% | 1.44x |
|
RMD
ResMed, Inc.
|
12.15% | 0.692 | 2.12% | 1.89x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 2.955 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LIVN
LivaNova Plc
|
$244.9M | $56.6M | -12.15% | -18.29% | 15.83% | $62.2M |
|
ABT
Abbott Laboratories
|
$5.9B | $2.2B | 22.49% | 29.06% | 19.03% | $2.3B |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
NVCR
NovoCure Ltd.
|
$122.5M | -$36M | -16.67% | -50.08% | -21.54% | $14.9M |
|
RMD
ResMed, Inc.
|
$808.9M | $462.3M | 22.25% | 25.6% | 34.62% | $411.5M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
LivaNova Plc vs. Competitors
-
Which has Higher Returns LIVN or ABT?
Abbott Laboratories has a net margin of 7.49% compared to LivaNova Plc's net margin of 14.07%. LivaNova Plc's return on equity of -18.29% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital LIVNLivaNova Plc68.44% $0.49 $1.6B ABTAbbott Laboratories52.05% $0.91 $64.2B -
What do Analysts Say About LIVN or ABT?
LivaNova Plc has a consensus price target of $70.64, signalling upside risk potential of 11.98%. On the other hand Abbott Laboratories has an analysts' consensus of $144.43 which suggests that it could grow by 15.97%. Given that Abbott Laboratories has higher upside potential than LivaNova Plc, analysts believe Abbott Laboratories is more attractive than LivaNova Plc.
Company Buy Ratings Hold Ratings Sell Ratings LIVNLivaNova Plc6 2 0 ABTAbbott Laboratories15 7 0 -
Is LIVN or ABT More Risky?
LivaNova Plc has a beta of 1.020, which suggesting that the stock is 2.023% more volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.716, suggesting its less volatile than the S&P 500 by 28.412%.
-
Which is a Better Dividend Stock LIVN or ABT?
LivaNova Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.89% to investors and pays a quarterly dividend of $0.59 per share. LivaNova Plc pays -- of its earnings as a dividend. Abbott Laboratories pays out 29.33% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LIVN or ABT?
LivaNova Plc quarterly revenues are $357.8M, which are smaller than Abbott Laboratories quarterly revenues of $11.4B. LivaNova Plc's net income of $26.8M is lower than Abbott Laboratories's net income of $1.6B. Notably, LivaNova Plc's price-to-earnings ratio is 38.16x while Abbott Laboratories's PE ratio is 15.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LivaNova Plc is 2.56x versus 4.98x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIVNLivaNova Plc2.56x 38.16x $357.8M $26.8M ABTAbbott Laboratories4.98x 15.66x $11.4B $1.6B
-
Which has Higher Returns LIVN or CATX?
Perspective Therapeutics, Inc. has a net margin of 7.49% compared to LivaNova Plc's net margin of -12425.36%. LivaNova Plc's return on equity of -18.29% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital LIVNLivaNova Plc68.44% $0.49 $1.6B CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About LIVN or CATX?
LivaNova Plc has a consensus price target of $70.64, signalling upside risk potential of 11.98%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 349.19%. Given that Perspective Therapeutics, Inc. has higher upside potential than LivaNova Plc, analysts believe Perspective Therapeutics, Inc. is more attractive than LivaNova Plc.
Company Buy Ratings Hold Ratings Sell Ratings LIVNLivaNova Plc6 2 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is LIVN or CATX More Risky?
LivaNova Plc has a beta of 1.020, which suggesting that the stock is 2.023% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock LIVN or CATX?
LivaNova Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LivaNova Plc pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LIVN or CATX?
LivaNova Plc quarterly revenues are $357.8M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. LivaNova Plc's net income of $26.8M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, LivaNova Plc's price-to-earnings ratio is 38.16x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LivaNova Plc is 2.56x versus 190.87x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIVNLivaNova Plc2.56x 38.16x $357.8M $26.8M CATXPerspective Therapeutics, Inc.190.87x -- $209K -$26M
-
Which has Higher Returns LIVN or NVCR?
NovoCure Ltd. has a net margin of 7.49% compared to LivaNova Plc's net margin of -22.29%. LivaNova Plc's return on equity of -18.29% beat NovoCure Ltd.'s return on equity of -50.08%.
Company Gross Margin Earnings Per Share Invested Capital LIVNLivaNova Plc68.44% $0.49 $1.6B NVCRNovoCure Ltd.73.25% -$0.33 $1.1B -
What do Analysts Say About LIVN or NVCR?
LivaNova Plc has a consensus price target of $70.64, signalling upside risk potential of 11.98%. On the other hand NovoCure Ltd. has an analysts' consensus of $24.79 which suggests that it could grow by 84.42%. Given that NovoCure Ltd. has higher upside potential than LivaNova Plc, analysts believe NovoCure Ltd. is more attractive than LivaNova Plc.
Company Buy Ratings Hold Ratings Sell Ratings LIVNLivaNova Plc6 2 0 NVCRNovoCure Ltd.4 2 0 -
Is LIVN or NVCR More Risky?
LivaNova Plc has a beta of 1.020, which suggesting that the stock is 2.023% more volatile than S&P 500. In comparison NovoCure Ltd. has a beta of 0.825, suggesting its less volatile than the S&P 500 by 17.463%.
-
Which is a Better Dividend Stock LIVN or NVCR?
LivaNova Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovoCure Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LivaNova Plc pays -- of its earnings as a dividend. NovoCure Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LIVN or NVCR?
LivaNova Plc quarterly revenues are $357.8M, which are larger than NovoCure Ltd. quarterly revenues of $167.2M. LivaNova Plc's net income of $26.8M is higher than NovoCure Ltd.'s net income of -$37.3M. Notably, LivaNova Plc's price-to-earnings ratio is 38.16x while NovoCure Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LivaNova Plc is 2.56x versus 2.31x for NovoCure Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIVNLivaNova Plc2.56x 38.16x $357.8M $26.8M NVCRNovoCure Ltd.2.31x -- $167.2M -$37.3M
-
Which has Higher Returns LIVN or RMD?
ResMed, Inc. has a net margin of 7.49% compared to LivaNova Plc's net margin of 26.1%. LivaNova Plc's return on equity of -18.29% beat ResMed, Inc.'s return on equity of 25.6%.
Company Gross Margin Earnings Per Share Invested Capital LIVNLivaNova Plc68.44% $0.49 $1.6B RMDResMed, Inc.60.56% $2.37 $7B -
What do Analysts Say About LIVN or RMD?
LivaNova Plc has a consensus price target of $70.64, signalling upside risk potential of 11.98%. On the other hand ResMed, Inc. has an analysts' consensus of $291.80 which suggests that it could grow by 19.38%. Given that ResMed, Inc. has higher upside potential than LivaNova Plc, analysts believe ResMed, Inc. is more attractive than LivaNova Plc.
Company Buy Ratings Hold Ratings Sell Ratings LIVNLivaNova Plc6 2 0 RMDResMed, Inc.8 7 1 -
Is LIVN or RMD More Risky?
LivaNova Plc has a beta of 1.020, which suggesting that the stock is 2.023% more volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.363%.
-
Which is a Better Dividend Stock LIVN or RMD?
LivaNova Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed, Inc. offers a yield of 0.93% to investors and pays a quarterly dividend of $0.60 per share. LivaNova Plc pays -- of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LIVN or RMD?
LivaNova Plc quarterly revenues are $357.8M, which are smaller than ResMed, Inc. quarterly revenues of $1.3B. LivaNova Plc's net income of $26.8M is lower than ResMed, Inc.'s net income of $348.5M. Notably, LivaNova Plc's price-to-earnings ratio is 38.16x while ResMed, Inc.'s PE ratio is 25.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LivaNova Plc is 2.56x versus 6.84x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIVNLivaNova Plc2.56x 38.16x $357.8M $26.8M RMDResMed, Inc.6.84x 25.02x $1.3B $348.5M
-
Which has Higher Returns LIVN or XTNT?
Xtant Medical Holdings, Inc. has a net margin of 7.49% compared to LivaNova Plc's net margin of 3.93%. LivaNova Plc's return on equity of -18.29% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital LIVNLivaNova Plc68.44% $0.49 $1.6B XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About LIVN or XTNT?
LivaNova Plc has a consensus price target of $70.64, signalling upside risk potential of 11.98%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 92.8%. Given that Xtant Medical Holdings, Inc. has higher upside potential than LivaNova Plc, analysts believe Xtant Medical Holdings, Inc. is more attractive than LivaNova Plc.
Company Buy Ratings Hold Ratings Sell Ratings LIVNLivaNova Plc6 2 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is LIVN or XTNT More Risky?
LivaNova Plc has a beta of 1.020, which suggesting that the stock is 2.023% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.
-
Which is a Better Dividend Stock LIVN or XTNT?
LivaNova Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LivaNova Plc pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LIVN or XTNT?
LivaNova Plc quarterly revenues are $357.8M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. LivaNova Plc's net income of $26.8M is higher than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, LivaNova Plc's price-to-earnings ratio is 38.16x while Xtant Medical Holdings, Inc.'s PE ratio is 76.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LivaNova Plc is 2.56x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LIVNLivaNova Plc2.56x 38.16x $357.8M $26.8M XTNTXtant Medical Holdings, Inc.0.85x 76.27x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
